Can perimenopause cause Ehlers-Danlos syndrome?

No, perimenopause does not cause Ehlers-Danlos syndrome (EDS). EDS is a group of inherited connective tissue disorders caused by genetic variants that affect the production, structure, or processing of collagen. The genetic difference is present from birth. No hormonal event in a woman's 40s or 50s creates or confers the underlying genetic change. This is important to be clear about.

However, perimenopause can significantly worsen EDS symptoms, and many women who have EDS report that the perimenopausal transition was a turning point where their condition became substantially harder to manage. For women who had a relatively mild or unrecognized EDS presentation, perimenopause can be the context in which symptoms become prominent enough to seek a diagnosis for the first time. This pattern is consistent with the hormonal biology involved.

Estrogen plays a critical role in collagen synthesis, quality, and maintenance throughout the body. It supports the production of collagen fibers, influences the enzymes that cross-link collagen into structurally stronger networks, and maintains the integrity of connective tissues in joints, blood vessels, skin, and organs. In women with EDS, whose collagen is already structurally compromised at a genetic level, estrogen's maintenance functions are more important precisely because the baseline collagen quality is lower. When estrogen levels fluctuate and begin to decline during perimenopause, the connective tissue support that estrogen was providing diminishes, and EDS symptoms worsen on a compromised foundation.

The practical consequences for women with EDS during perimenopause can include several specific changes. Joint hypermobility and instability often worsen as estrogen-supported ligament tensile strength decreases. Joints that were previously manageable may begin to subluxate (partially dislocate) more frequently, with less provocation. Musculoskeletal pain typically intensifies as the body compensates for greater joint instability through increased muscle guarding and tension. Recovery from minor injuries and microtrauma may slow.

For women with hypermobile EDS (hEDS) who also have dysautonomia, including postural orthostatic tachycardia syndrome (POTS), perimenopause is often particularly difficult. Estrogen fluctuations directly affect autonomic nervous system regulation and vascular tone, and POTS symptoms frequently worsen significantly during perimenopause. Symptoms including rapid heart rate on standing, dizziness, brain fog, and exercise intolerance can all escalate.

Skin-related features of EDS, including easy bruising, slow wound healing, and hyperextensible skin, can worsen as collagen synthesis decreases with estrogen decline. Fatigue, already a major feature of EDS, often intensifies during perimenopause, partly from the hormonal changes and partly from the compounded effect of worsened sleep from pain and autonomic instability.

For women with EDS, physiotherapy focused on joint stabilization and appropriate muscle strengthening, rather than flexibility, becomes even more important during perimenopause. Stabilizing exercises for the hips, shoulders, knees, and core can compensate partially for increased ligament laxity. Pacing activities to avoid the boom-bust cycle that worsens pain and fatigue is important. Sleep protection deserves specific attention, including addressing perimenopausal night sweats and insomnia, since poor sleep worsens pain sensitivity and fatigue across all connective tissue conditions.

Hormone therapy is worth a careful, individualized conversation for women with EDS experiencing significant worsening during perimenopause. Some clinicians and patients report meaningful stabilization of joint symptoms and reduction in pain with hormone therapy, though controlled trial data in the EDS population specifically is limited. The decision requires weighing individual risk-benefit considerations.

Tracking your symptoms over time, using a tool like PeriPlan, can help you document changes in joint stability, pain levels, fatigue, and other EDS features across the perimenopausal transition, providing specific data for your care team.

When to talk to your doctor:

If you have EDS and notice significant worsening of joint instability, pain, autonomic symptoms, or fatigue during perimenopause, bring this to your specialist promptly rather than assuming it is an inevitable deterioration. If you have not been evaluated for EDS but experience hypermobile joints, chronic widespread pain, easy bruising, and a disproportionate perimenopausal symptom burden, ask for a referral to a geneticist or connective tissue specialist. Many women with EDS are not diagnosed until midlife, when perimenopausal symptom amplification brings their connective tissue vulnerability to clinical attention for the first time, making perimenopause paradoxically an opportunity for formal diagnosis and access to appropriate specialist support and management.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.